Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production
出版年份 2023 全文链接
标题
Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production
作者
关键词
-
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-26
DOI
10.1007/s13300-023-01491-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms
- (2023) Elena Osto et al. PHARMACOLOGICAL RESEARCH
- Normal HDL cholesterol efflux and anti-inflammatory capacities in type 2 diabetes despite lipidomic abnormalities
- (2022) Damien Denimal et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
- (2022) Hao Zhaohu et al. Journal of Diabetes Research
- Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
- (2022) Lucia Leccisotti et al. Cardiovascular Diabetology
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
- (2022) Teresa Salvatore et al. Biomedicines
- Impaired coronary flow reserve in patients with poor type 2 diabetes control: Preliminary results from prospective microvascular dysfunction registry
- (2022) Łukasz Niewiara et al. Cardiology Journal
- Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
- (2021) Gian Pio Sorice et al. Diabetes Therapy
- Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
- (2021) Andrea Natali et al. Cardiovascular Diabetology
- LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters
- (2020) Lorenzo Arnaboldi et al. ATHEROSCLEROSIS
- The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol
- (2020) Kristien E. C. Bouter et al. DIABETES OBESITY & METABOLISM
- Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials
- (2020) Adriana Sánchez-García et al. PHARMACOLOGICAL RESEARCH
- Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome
- (2019) Alice Ossoli et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Sodium‐glucose co‐transporter inhibitors: Medications that mimic fasting for cardiovascular prevention
- (2019) Andrea Giaccari DIABETES OBESITY & METABOLISM
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dysfunctional HDL as a therapeutic target for atherosclerosis prevention
- (2018) Alice Ossoli et al. CURRENT MEDICINAL CHEMISTRY
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2015) Nobuya Inagaki et al. ADVANCES IN THERAPY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol Efflux and Atheroprotection
- (2012) Robert S. Rosenson et al. CIRCULATION
- Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials
- (2011) Martin K Reriani et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
- (2010) Laura Calabresi et al. CURRENT PHARMACEUTICAL DESIGN
- Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
- (2009) Sajoscha A. Sorrentino et al. CIRCULATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started